AFP’s 2022 results: 5% growth in commercial revenues, new tensions on costs
At its meeting on 20 April 2023, AFP's Board of Directors approved the accounts for the 2022 financial year, which confirm the Agency's continued financial recovery.
Washington (AFP) | 10/12/2025 - 22:06:58 | Trump says had 'pretty strong words' with Europeans on Ukraine
Kinshasa (AFP) | 10/12/2025 - 22:03:14 | Rwanda-backed M23 seizes key points of strategic east DR Congo city: sources
Doha (AFP) | 10/12/2025 - 22:01:43 | Hamas proposes weapons 'freeze' in return for long-term truce: leader to Al Jazeera
Kyiv (AFP) | 10/12/2025 - 21:53:20 | Kyiv sent US updated plan to end the war: two Ukrainian officials to AFP
Washington (AFP) | 10/12/2025 - 21:27:58 | Powell says real wage growth needed to ease affordability concerns
Washington (AFP) | 10/12/2025 - 21:13:59 | Trump says US has seized tanker off coast of Venezuela
Washington (AFP) | 10/12/2025 - 21:08:45 | US Fed chair says rate cut a 'close call' given state of economy
Washington (AFP) | 10/12/2025 - 20:50:36 | US Fed chair says 'well positioned' to wait on further rate cuts
Oslo (AFP) | 10/12/2025 - 20:30:46 | Nobel Peace laureate Machado to speak to the media Thursday at 0915 GMT: Norway govt
Washington (AFP) | 10/12/2025 - 20:03:53 | Divided US Fed makes third straight rate cut on jobs risk
At its meeting on 20 April 2023, AFP's Board of Directors approved the accounts for the 2022 financial year, which confirm the Agency's continued financial recovery.
AFP strongly condemns the detention of its journalist and photographer Yasin Akgül and calls for his immediate release. This is a serious attack on the freedom of the media.
After training with journalists from Agence France-Presse and the Austrian news agency APA, Ukraine’s largest news agency Ukrinform has started writing its own fact-check articles in an effort to confront a wave of war-related disinformation.
Experian® today released its 2026 Data Breach Industry Forecast, offering a look at the evolving cyber threat landscape. The predictions address how the coming year could usher in a new wave of sophisticated attacks driven by artificial intelligence along with other threats and vulnerabilities including quantum computing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202474758/en/Experian's 2026 Data Breach Industry Forecast Now ...
Incyte (Nasdaq:INCY) today announced new data from the Phase 3b TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib cream) in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs). These data will be presented during the Systemic and New Therapies for Atopic Dermatitis session on Sunday, October 26 at 10:55 a.m. AEDT (Saturday, October 25 at 7...
Yokogawa Electric Corporation (TOKYO: 6841) announces that its subsidiary, Yokogawa Saudi Arabia, has been awarded a contract by the Royal Commission for Riyadh City to provide the necessary systems and services for the main command and control center of the Green Riyadh project*. Led by the Government of Saudi Arabia, this national initiative is a key element of Saudi Vision 2030. Its objective is to transform Riyadh into one of the world’s most livable cities through urban greening, enabling ...
The NPPA (National Press Photographers Association) Awards have honoured AFP photographer Luis Tato with three prizes in the Science, Science Story and Politics Story categories.
Egle Therapeutics SAS (Egle), a clinical-stage biotechnology company developing precision medicines that modulate regulatory T cells (Tregs) to restore immune balance, today announced dosing of the first healthy volunteer in the Phase 1 clinical study of EGL-003, an IL‑2⍺-biased mutein designed to selectively activate Tregs while limiting effector T cell stimulation, as a potential treatment for atopic dermatitis. The open-label, multi-center Phase 1 trial begins with a single ascending dose p...